Five things for pharma marketers to know: Thursday, June 21, 2018

Share this content:

GoodRx is in talks with several parties to be acquired for as much as $3 billion. The health tech startup provides a way for people to find prescription drugs for a lower price through drug discount cards. (CNBC)


Heron Therapeutics has received breakthrough therapy designation from the FDA for its pain treatment. The drug met primary endpoints in a study for pain with total knee arthroplasty and one for breast augmentation. (MarketWatch)


Novo Nordisk's diabetes pill has proven to be more effective than Merck's Januvia and its own injectable Victoza in a series of clinical trials. The diabetes pill demonstrated blood-sugar reduction and weight loss during clinical trials. Analysts believe this pill could be a multibillion-dollar blockbuster. (Reuters)


BrainStorm Cell Therapeutics may be the first to sell an unproven drug under the Right to Try law for a profit. The biotech company is developing a treatment for ALS, known as NurOwn, which could cost as much as $300,000, according to BrainStorm's CEO. The therapy is in a Phase 3 clinical trial. (STAT)


Insurers are planning to increase their presence on Affordable Care Act marketplaces in 2019. Companies such as Centene, Molina Healthcare, and Oscar Health are selling coverage in additional states. (Wall Street Journal)

Share this content:
Scroll down to see the next article